@article{BazihizinaBoehmMessereretal.2022,
  author    = {Bazihizina, Nadia and B{\"o}hm, Jennifer and Messerer, Maxim and Stigloher, Christian and M{\"u}ller, Heike M. and Cuin, Tracey Ann and Maierhofer, Tobias and Cabot, Joan and Mayer, Klaus F. X. and Fella, Christian and Huang, Shouguang and Al-Rasheid, Khaled A. S. and Alquraishi, Saleh and Breadmore, Michael and Mancuso, Stefano and Shabala, Sergey and Ache, Peter and Zhang, Heng and Zhu, Jian-Kang and Hedrich, Rainer and Scherzer, S{\"o}nke},
  title     = {Stalk cell polar ion transport provide for bladder-based salinity tolerance in Chenopodium quinoa},
  series = {New Phytologist},
  volume    = {235},
  journal   = {New Phytologist},
  number    = {5},
  doi       = {10.1111/nph.18205},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-287222},
  pages     = {1822 -- 1835},
  year      = {2022},
  abstract  = {Chenopodium quinoa uses epidermal bladder cells (EBCs) to sequester excess salt. Each EBC complex consists of a leaf epidermal cell, a stalk cell, and the bladder. Under salt stress, sodium (Na\(^{+}\)), chloride (Cl\(^{-}\)), potassium (K\(^{+}\)) and various metabolites are shuttled from the leaf lamina to the bladders. Stalk cells operate as both a selectivity filter and a flux controller. In line with the nature of a transfer cell, advanced transmission electron tomography, electrophysiology, and fluorescent tracer flux studies revealed the stalk cell's polar organization and bladder-directed solute flow. RNA sequencing and cluster analysis revealed the gene expression profiles of the stalk cells. Among the stalk cell enriched genes, ion channels and carriers as well as sugar transporters were most pronounced. Based on their electrophysiological fingerprint and thermodynamic considerations, a model for stalk cell transcellular transport was derived.},
  language  = {en}
}
@phdthesis{Mayer2006,
  author    = {Mayer, Christian},
  title     = {Pfadbildung durch invasive Melanomzellen : Matrixdefekte, Zellfragmente und erleichterte Migration},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-19657},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2006},
  abstract  = {Die metastatische Invasion von Tumorzellen durch die extrazellul{\"a}re Matrix von Geweben erfordert aktive Zellmigration sowie h{\"a}ufig auch den Umbau der Gewebestruktur. In dieser Arbeit sollte mittels metastasierender MV3-Melonomzellen in einem 3D-Kollagenmatrixmodell der migrationsassozierte Matrixumbau zellul{\"a}r und molekular untersucht werden, insbesondere die physikalische Charakterisierung gebildeter Matrixdefekte, die molekulare Identifi kation freigesetzter Zellbestandteile, sowie den Einfluß pfadbildender Zellen auf die Invasion nachfolgender Zellen. Die Daten zeigen, daß MV3-Melanomzellen w{\"a}hrend der Migration durch ein 3DKollagengewebe komplette Zellfragmente in zur{\"u}ckbleibenden r{\"o}hrenf{\"o}rmigen Trassen deponieren. Diese beinhalteten Zytoplasma und teils Zytoskelett umgeben von intakter Zellmembran mit integrierten Oberfl{\"a}chenrezeptoren wie \&\#946;1-Integrinen, nicht jedoch DNA-Material. Der Durchmesser der Fragmente lag {\"u}berwiegend bei 1-5 \&\#956;m, selten {\"u}ber 10 \&\#956;m, entsprechend unspezifisch freigesetzter Zellfragmente, die w{\"a}hrend der Migration vom Zellhinterende abgeschilftet werden. In einem Sph{\"a}roidmodell ließen sich mehrere Invasionsfronten nachweisen, in denen einer ersten pfadbildenden Zelle entlang neu gebildeter Matrixtrassen weitere Zellen den gleichen pr{\"a}formierten Trassen folgten. Die videomikroskopischen Befunde wurden mittels Konfokalmikroskopie best{\"a}tigt. Eine erwartete h{\"o}here Migrationsgeschwindigkeit der nachfolgenden Zellen in dem pr{\"a}formierten Pfad best{\"a}tigte sich jedoch nicht. Somit f{\"u}hrt die Invasion von MV3-Melanomzellen zur Ausbildung strukturell umgebauter Matrixtrassen, die aus Matrixdefekt freigesetzten Zellfragmenten und angrenzender Extrazellul{\"a}rmatrix bestehen und nachfolgenden Zellen als Leitstruktur f{\"u}r eine orientierte Form der Invasion dienen (Kettenwanderung). Diese Befunde beleuchten die Dynamik von Zellarrangements {\"a}hnlich dem Invasionsmuster in histopathologischen Tumorproben.},
  language  = {de}
}
@phdthesis{Mayer2006,
  author    = {Mayer, Christian},
  title     = {Alternative Keimbildner f{\"u}r transparente, farblose LAS-Glaskeramiken},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-19206},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2006},
  abstract  = {In LAS-Glaskeramiken, die besondere Verbreitung bei Anwendungen als Kochfl{\"a}che, Brandschutzglas und Bauteil f{\"u}r pr{\"a}zise Optik gefunden haben, werden vorrangig die Keimbildner TiO2 und ZrO2 eingesetzt. Transparente Glaskeramiken weisen jedoch eine mehr oder weniger starke Gelbf{\"a}rbung auf, die vorrangig aus dem Einsatz von TiO2 zusammen mit unvermeidbaren Fe2O3-Verunreinigungen resultiert. Die Minimierung dieser Gelbf{\"a}rbung gewinnt zunehmend an Bedeutung. Ziel der vorliegenden Arbeit ist die Pr{\"u}fung, inwiefern die Verringerung der Eigenfarbe einer transparenten LAS-Glaskeramik durch Ersatz des f{\"a}rbenden Keimbildners TiO2 durch einen weniger f{\"a}rbenden Keimbildner m{\"o}glich ist, ohne dass das gute Keimbildungsverm{\"o}gen beeintr{\"a}chtigt wird. Verschiedene alternative Keimbildner zu TiO2 wurden stets in Kombination mit ZrO2 hinsichtlich Keimbildungsverm{\"o}gen und F{\"a}rbung/Transmission untersucht sowie andere Kerneigenschaften im Vergleich zu der Standardkeimbildnerkombination TiO2/ZrO2 diskutiert. Signifikante Vorteile bzgl. Eigenfarbe und Transmission gegen{\"u}ber dem TiO2/ZrO2-gekeimten Referenzmaterial konnten nur bei der Keimbildnerkombination SnO2/ZrO2 gefunden werden. Die Transmission ist mit 89\% statt 87\% beim Referenzmaterial h{\"o}her, die Eigenfarbe ist mit dem Farbort a*/b* = -0,1/+2,3 deutlich n{\"a}her am Unbuntpunkt als die Referenz a*/b* = -0,6/+5,1, der Yellowness Index reduziert sich von 9,5 auf 4,6.},
  subject      = {Glaskeramik},
  language  = {de}
}
@article{RauchSalzwedelBjarnasonWehrensetal.2021,
  author    = {Rauch, Bernhard and Salzwedel, Annett and Bjarnason-Wehrens, Birna and Albus, Christian and Meng, Karin and Schmid, Jean-Paul and Benzer, Werner and Hackbusch, Matthes and Jensen, Katrin and Schwaab, Bernhard and Altenberger, Johann and Benjamin, Nicola and Bestehorn, Kurt and Bongarth, Christa and D{\"o}rr, Gesine and Eichler, Sarah and Einwang, Hans-Peter and Falk, Johannes and Glatz, Johannes and Gielen, Stephan and Grilli, Maurizio and Gr{\"u}nig, Ekkehard and Guha, Manju and Hermann, Matthias and Hoberg, Eike and H{\"o}fer, Stefan and Kaemmerer, Harald and Ladwig, Karl-Heinz and Mayer-Berger, Wolfgang and Metzendorf, Maria-Inti and Nebel, Roland and Neidenbach, Rhoia Clara and Niebauer, Josef and Nixdorff, Uwe and Oberhoffer, Renate and Reibis, Rona and Reiss, Nils and Saure, Daniel and Schlitt, Axel and V{\"o}ller, Heinz and K{\"a}nel, Roland von and Weinbrenner, Susanne and Westphal, Ronja},
  title     = {Cardiac rehabilitation in German speaking countries of Europe — evidence-based guidelines from Germany, Austria and Switzerland LLKardReha-DACH — Part 1},
  series = {Journal of Clinical Medicine},
  volume    = {10},
  journal   = {Journal of Clinical Medicine},
  number    = {10},
  issn      = {2077-0383},
  doi       = {10.3390/jcm10102192},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239709},
  year      = {2021},
  abstract  = {Background: Although cardiovascular rehabilitation (CR) is well accepted in general, CR-attendance and delivery still considerably vary between the European countries. Moreover, clinical and prognostic effects of CR are not well established for a variety of cardiovascular diseases. Methods: The guidelines address all aspects of CR including indications, contents and delivery. By processing the guidelines, every step was externally supervised and moderated by independent members of the "Association of the Scientific Medical Societies in Germany" (AWMF). Four meta-analyses were performed to evaluate the prognostic effect of CR after acute coronary syndrome (ACS), after coronary bypass grafting (CABG), in patients with severe chronic systolic heart failure (HFrEF), and to define the effect of psychological interventions during CR. All other indications for CR-delivery were based on a predefined semi-structured literature search and recommendations were established by a formal consenting process including all medical societies involved in guideline generation. Results: Multidisciplinary CR is associated with a significant reduction in all-cause mortality in patients after ACS and after CABG, whereas HFrEF-patients (left ventricular ejection fraction <40\%) especially benefit in terms of exercise capacity and health-related quality of life. Patients with other cardiovascular diseases also benefit from CR-participation, but the scientific evidence is less clear. There is increasing evidence that the beneficial effect of CR strongly depends on "treatment intensity" including medical supervision, treatment of cardiovascular risk factors, information and education, and a minimum of individually adapted exercise volume. Additional psychologic interventions should be performed on the basis of individual needs. Conclusions: These guidelines reinforce the substantial benefit of CR in specific clinical indications, but also describe remaining deficits in CR-delivery in clinical practice as well as in CR-science with respect to methodology and presentation.},
  language  = {en}
}
@article{WeisschuhMayerStrometal.2016,
  author    = {Weisschuh, Nicole and Mayer, Anja K. and Strom, Tim M. and Kohl, Susanne and Gl{\"o}ckle, Nicola and Schubach, Max and Andreasson, Sten and Bernd, Antje and Birch, David G. and Hamel, Christian P. and Heckenlively, John R. and Jacobson, Samuel G. and Kamme, Christina and Kellner, Ulrich and Kunstmann, Erdmute and Maffei, Pietro and Reiff, Charlotte M. and Rohrschneider, Klaus and Rosenberg, Thomas and Rudolph, G{\"u}nther and V{\´a}mos, Rita and Vars{\´a}nyi, Bal{\´a}zs and Weleber, Richard G. and Wissinger, Bernd},
  title     = {Mutation Detection in Patients with Retinal Dystrophies Using Targeted Next Generation Sequencing},
  series = {PLoS ONE},
  volume    = {11},
  journal   = {PLoS ONE},
  number    = {1},
  doi       = {10.1371/journal.pone.0145951},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-167398},
  pages     = {e0145951},
  year      = {2016},
  abstract  = {Retinal dystrophies (RD) constitute a group of blinding diseases that are characterized by clinical variability and pronounced genetic heterogeneity. The different nonsyndromic and syndromic forms of RD can be attributed to mutations in more than 200 genes. Consequently, next generation sequencing (NGS) technologies are among the most promising approaches to identify mutations in RD. We screened a large cohort of patients comprising 89 independent cases and families with various subforms of RD applying different NGS platforms. While mutation screening in 50 cases was performed using a RD gene capture panel, 47 cases were analyzed using whole exome sequencing. One family was analyzed using whole genome sequencing. A detection rate of 61\% was achieved including mutations in 34 known and two novel RD genes. A total of 69 distinct mutations were identified, including 39 novel mutations. Notably, genetic findings in several families were not consistent with the initial clinical diagnosis. Clinical reassessment resulted in refinement of the clinical diagnosis in some of these families and confirmed the broad clinical spectrum associated with mutations in RD genes.},
  language  = {en}
}
@article{EckardtStasikKrameretal.2021,
  author    = {Eckardt, Jan-Niklas and Stasik, Sebastian and Kramer, Michael and R{\"o}llig, Christoph and Kr{\"a}mer, Alwin and Scholl, Sebastian and Hochhaus, Andreas and Crysandt, Martina and Br{\"u}mmendorf, Tim H. and Naumann, Ralph and Steffen, Bj{\"o}rn and Kunzmann, Volker and Einsele, Hermann and Schaich, Markus and Burchert, Andreas and Neubauer, Andreas and Sch{\"a}fer-Eckart, Kerstin and Schliemann, Christoph and Krause, Stefan W. and Herbst, Regina and H{\"a}nel, Mathias and Frickhofen, Norbert and Noppeney, Richard and Kaiser, Ulrich and Baldus, Claudia D. and Kaufmann, Martin and R{\´a}cil, Zdenek and Platzbecker, Uwe and Berdel, Wolfgang E. and Mayer, Jiř{\´i} and Serve, Hubert and M{\"u}ller-Tidow, Carsten and Ehninger, Gerhard and St{\"o}lzel, Friedrich and Kroschinsky, Frank and Schetelig, Johannes and Bornh{\"a}user, Martin and Thiede, Christian and Middeke, Jan Moritz},
  title     = {Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia},
  series = {Cancers},
  volume    = {13},
  journal   = {Cancers},
  number    = {9},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13092095},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236735},
  year      = {2021},
  abstract  = {Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The BCL6 corepressor (BCOR) and its homolog, the BCL6 corepressor-like 1 (BCORL1), have been reported to be rare but recurrent mutations in AML. Previously, smaller studies have reported conflicting results regarding impacts on outcomes. Here, we retrospectively analyzed a large cohort of 1529 patients with newly diagnosed and intensively treated AML. BCOR and BCORL1 mutations were found in 71 (4.6\%) and 53 patients (3.5\%), respectively. Frequently co-mutated genes were DNTM3A, TET2 and RUNX1. Mutated BCORL1 and loss-of-function mutations of BCOR were significantly more common in the ELN2017 intermediate-risk group. Patients harboring loss-of-function mutations of BCOR had a significantly reduced median event-free survival (HR = 1.464 (95\%-Confidence Interval (CI): 1.005-2.134), p = 0.047), relapse-free survival (HR = 1.904 (95\%-CI: 1.163-3.117), p = 0.01), and trend for reduced overall survival (HR = 1.495 (95\%-CI: 0.990-2.258), p = 0.056) in multivariable analysis. Our study establishes a novel role for loss-of-function mutations of BCOR regarding risk stratification in AML, which may influence treatment allocation.},
  language  = {en}
}